04:55 PM EST, 02/18/2025 (MT Newswires) -- Kevin Joseph Fitzgerald, Chief Scientific Officer & Executive Vice President, Head of Research, on February 13, 2025, sold 2,103 shares in Alnylam Pharmaceuticals ( ALNY ) for $531,448. Following the Form 4 filing with the SEC, Fitzgerald has control over a total of 13,418 common shares of the company, with 12,881 shares held directly and 537 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1178670/000173527625000010/xslF345X05/edgardoc.xml